Payer Expansion Leverage the Highmark reimbursement milestone for Canvas Dx as a proof point to engage additional payers and Medicaid/Medicare programs, positioning the FDA‑authorized autism diagnostic AI as a cost‑effective option that supports earlier, better outcomes.

Strategic Partnerships Capitalize on the Catalight network of practitioners to accelerate adoption and referrals for post‑diagnosis services; pursue joint pilots, co‑marketing, and workflow integrations to strengthen the funnel from screening to treatment.

Leadership Access Use recent leadership appointments to open conversations with large pediatric health systems; target CMOs, Medical Directors, and VP Medical Affairs with enterprise demos that highlight clinical accuracy, fairness, and strong governance of the AI tool.

Cross Sell Potential Promote the whole‑child AI platform as a multi‑condition solution spanning autism, speech and language, ADHD, and anxiety, enabling bundled offerings and easier EHR integration to expand footprint across pediatric clinics.

Market Readiness Position Cognoa within the growing AI in pediatrics trend, emphasizing FDA authorization and early‑diagnosis value to win pilots with clinics, school‑based health programs, and payers looking to reduce time to diagnosis and improve outcomes.